Literature DB >> 35223647

Endothelial Nitric Oxide Synthase 4a/B Polymorphism and Its Interaction with Enos G894T Variants in Type 2 Diabetic Patients: Modifying the Risk of Diabetic Nephropathy.

Mahsa Mohammadi1,2, Hamid Yaghooti3,4, Azim Adibmanesh3, Narges Mohammadtaghvaie3,4, Ali Karimi Akhormeh3, Maryam Eslami1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35223647      PMCID: PMC8837896          DOI: 10.18502/ijph.v51i1.8318

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

Diabetic Nephropathy (DN) is one of the most important microvascular complications of T2DM. A candidate gene implicated to play a major role in DN susceptibility, is endothelial nitric oxide synthase (eNOS) gene (1). eNOS polymorphisms is associated with endothelial dysfunction and diabetic complications (retinopathy and neuropathy). In recent years, several polymorphisms of the eNOS gene have been identified. G894T, the missense mutation in exon 7 accurs in position 894 of the eNOS gene corresponds to a guanine to thymine conversion and leads to a glutamine to aspartate substitution in position 298 of the protein (Glu298Asp). Another studied polymorphism is 5’ end of eNOS gene (27bp repeats). This polymorphism regulates eNOS expression through small interference RNA (sirRNA) (2). Some studies have confirmed the relationship between eNOS genetic polymorphisms and DN (3, 4). So we investigated the association of 4a/b polymorphism and the risk of T2DM and DN in diabetic patients in southwest of Iran. Furthermore, we wanted to measure the kidney function. A total number of 132 diabetic patients (66 patients with DN, 66 patients without DN) of Arab ethnicity referred to the Golestan Hospital of Ahvaz, southern Iran were enrolled. Informed consent for participation was obtained from all the subjects. The study was approved by the ethics committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1395.200). Blood samples were taken in the morning after overnight fasting for measuring Fasting blood glucose, HbA1c, BUN, Serum creatinine, microalbumin, Serum cystatin C levels and eGFR. Total genomic DNA was extracted from leukocyte fraction using a standard technique. Genotyping for 4a/4b was performed by PCR and genotyping for G894T based on the PCR-RFLP methods using Ban II digestion. Elevated serum creatinine, BUN, cystatin C, microalbumin levels and decreased estimated GFR (as markers of kidney damage) were observed in people with the T2D as compared to healthy control group. Significant associations with the susceptibility to T2DM were detected for G894T and 4a/4b polymorphisms, (OR=1.86 95%CI=1.16–2.99, P=0.01) and (OR=1.92 95%CI=1.18–3.2, P=0.0009), respectively. Further we did not find a significant association with DN as the microvascular complication of T2DM, (OR = 1.1 95% CI 0.7–1.8, P=0.6) and (OR = 0.92 95% CI 0.6–1.5, P=0.7), respectively. In contradiction to our study in Indian and Malaysian people (3, 5), revealed eNOS genotypes have significant effects on the development of nephropathy in type 2 diabetes patients. Furthermore we demonstrated the risk of DN in T2DM in the presence of eNOS T alleles and eNOS a alleles up to 1.8-fold (P=0.049) and 4.6-fold(P=0.029), respectively. Concomitant presence of the two variants was not associated with increased risk of T2DM and DN (Table 1).
Table 1:

Interaction of eNOS a with eNOS T alleles in association with diabetic nephropathy

eNOS a eNOS T T2DM patients without nephropathy N(%)T2DM patient with nephropathy N(%) OR(95% CI) P-value Adjusted ORa(95% CI) P-valuea
++27(40.9)12(18.2)0.89(0.3–2.9)0.81.04(0.7–1.6)0.858
+17(25.8)29(43.9)3.4(1.1–10.8)0.0361.8(1–3.4)0.049
+10(15.2)19(28.8)3.8(1.1–13.2)0.0354.6(1.2–18.5)0.029
12(18.2)6(9.1)1.0(ref)1.0(ref)

Data in n (%),aAdjusted for age, sex, BMI, HbA1c

Interaction of eNOS a with eNOS T alleles in association with diabetic nephropathy Data in n (%),aAdjusted for age, sex, BMI, HbA1c
  5 in total

1.  Associations between endothelial nitric oxide synthase polymorphisms and risk of diabetic nephropathy: an updated meta-analysis.

Authors:  Yong Zhang; Hou-Qin Xiao; Xian-Tao Zeng; Hong-Xia Zuo; Yan-Cheng Xu
Journal:  Ren Fail       Date:  2015-10-21       Impact factor: 2.606

Review 2.  A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.

Authors:  Riccardo Lacchini; Pamela S Silva; Jose E Tanus-Santos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-03-04       Impact factor: 4.080

3.  Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians.

Authors:  Tarunveer Singh Ahluwalia; Monica Ahuja; Taranjit Singh Rai; Harbir Singh Kohli; Kamal Sud; Anil Bhansali; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2008-04-10       Impact factor: 3.396

4.  CNDP1, NOS3, and MnSOD Polymorphisms as Risk Factors for Diabetic Nephropathy among Type 2 Diabetic Patients in Malaysia.

Authors:  Mohd Jokha Yahya; Patimah Binti Ismail; Norshariza Binti Nordin; Abdah Binti Md Akim; Wan Shaariah Binti Md Yusuf; Noor Lita Binti Adam; Nurul Fasihah Zulkifli
Journal:  J Nutr Metab       Date:  2019-01-03

5.  Nitric oxide system and diabetic nephropathy.

Authors:  Bruno Schmidt Dellamea; Cristiane Bauermann Leitão; Rogério Friedman; Luis Henrique Canani
Journal:  Diabetol Metab Syndr       Date:  2014-02-12       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.